Advances in Treating Lymphoma From the ASH Annual Meeting 2019

January 16, 2020
Brielle Gregory, ASCO staff

The 2019 American Society of Hematology (ASH) Annual Meeting and Exposition was held December 7 to 10 in Orlando, Florida. This meeting draws together experts from around the world to discuss new advances in the treatment of blood-related diseases, including cancers of the blood and bone marrow.

In this podcast, Michael Williams, MD, ScM, describes 4 findings presented at the meeting, including new ways of managing localized diffuse large B-cell lymphoma (DLBCL), a new treatment approach for recurrent, or relapsed, mantle cell lymphoma, and a new medication for the treatment of highly resistant relapsed lymphoma.

  • Two studies used PET scans to see if radiation therapy was needed in people with localized DLBCL after treatment with systemic therapy. [2:47]

  • An update on a study that used a combination of targeted therapies, ibrutinib (Imbruvica) and venetoclax (Venclexta), to treat relapsed mantle cell lymphoma. [9:16]

  • A study about a new treatment for highly resistant, relapsed non-Hodgkin lymphoma, called mosunetuzumab, a bispecific antibody. This immunotherapy pulls together the body’s T cells and lymphoma B cells, so that the T cells can destroy the cancer. [11:27]

Dr. Williams is the Byrd S. Leavell Professor of Medicine and Professor of Pathology at the University of Virginia School of Medicine. He serves as chief of the Hematology/Oncology Division, physician lead for the Cancer Service Line, and associate director for Clinical Affairs in the UVA Cancer Center. Dr. Williams is the Cancer.Net Associate Editor for Lymphoma.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.